Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 13.5% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (28.2%)
  • Dividend yield for the last twelve months 0.7%
  • Free cash flow yield -1.5% (LTM)
  • Share price is 193.5% higher than minimum and 14.8% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (52.5x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $2 385.6 mln (-0.098% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (-1.0%)818
year average price 839.59  


year start price 763.96 2024-04-02

min close price 724.87 2024-04-25

max close price 960.02 2024-08-30

current price 819.77 2025-04-01
Common stocks: 900 605 000

Dividend Yield:  0.7%
FCF Yield LTM: -1.5%
EV / LTM EBITDA: 52.5x
EV / EBITDA annualized: 34.5x
Last revenue growth (y/y):  +44.7%
Last growth of EBITDA (y/y):  -17.7%
Historical revenue growth:  +17.8%
Historical growth of EBITDA:  +38.7%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 736 695
Net Debt ($m): 33 724
EV (Enterprise Value): 770 419
EBITDA LTM ($m): 14 666
EV / LTM EBITDA: 52.5x
Price to Book: 52.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-04-01cnbc.com

Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro

2025-04-01fool.com

Where Will Eli Lilly Be in 1 Year?

2025-04-01reuters.com

Lilly sues two compounders over copies of weight-loss drugs

2025-03-30reuters.com

Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial

2025-03-30prnewswire.com

Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels

2025-03-30fool.com

1 Growth Stock With Major Catalysts on the Way to Buy and Hold

2025-03-29finbold.com

2 healthcare safe bets to buy ahead of Trump's pharmaceutical tariffs

2025-03-25prnewswire.com

Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

2025-03-24proactiveinvestors.co.uk

Is Ozempic maker Novo Nordisk losing to Eli Lilly in the obesity wars?

2025-03-23fool.com

Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data